"Ibudilast"@en . . "Ke tas"@en . "investigational"@en . . . "19 hours"@en . "50847-11-5"@en . " "@en . . . "Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan."@en . . . . . "Humans and other mammals"@en . . . . . "Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of [nitric oxide] synthesis and reduction in reactive oxygen species."@en . . . . . . "Ketas"@en . "3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine"@en . "Ibudilast"@en . "AV-411"@en . . "approved"@en . "3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine"@en . . "Ibudilastum"@en . . . . . "Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-"@en . . "Eyevinal"@en . "Ketas (TN)"@en . . . . . . . "2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine"@en . . . . . . "Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia"@en . "MN-166"@en . "Tocris-1694"@en . "For the treatment of multiple sclerosis, asthma, and cerebrovascular disease."@en . . .